Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Notes Payables: 2014-2019

Historic Notes Payables for Zevra Therapeutics (ZVRA) over the last 4 years, with Dec 2019 value amounting to $7.0 million.

  • Zevra Therapeutics' Notes Payables rose 881.24% to $65.9 million in Q3 2020 from the same period last year, while for Sep 2020 it was $65.9 million, marking a year-over-year increase of 881.24%. This contributed to the annual value of $7.0 million for FY2019, which is 109.45% up from last year.
  • As of FY2019, Zevra Therapeutics' Notes Payables stood at $7.0 million, which was up 109.45% from $3.3 million recorded in FY2018.
  • Zevra Therapeutics' Notes Payables' 5-year high stood at $7.0 million during FY2019, with a 5-year trough of $1.4 million in FY2015.
  • For the 2-year period, Zevra Therapeutics' Notes Payables averaged around $5.2 million, with its median value being $5.2 million (2018).
  • Data for Zevra Therapeutics' Notes Payables shows a peak YoY soared of 321.23% (in 2015) over the last 5 years.
  • Yearly analysis of 3 years shows Zevra Therapeutics' Notes Payables stood at $1.4 million in 2015, then reached $3.3 million in 2018, then spiked by 109.45% to $7.0 million in 2019.